메뉴 건너뛰기




Volumn 16, Issue 12, 2010, Pages 2168-2172

Lost in translation: Helping patients understand the risks of inflammatory bowel disease therapy

Author keywords

communication; Crohn's; perception; risk; ulcerative colitis

Indexed keywords

AZATHIOPRINE; IMMUNOMODULATING AGENT; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

EID: 78649557755     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21305     Document Type: Review
Times cited : (24)

References (31)
  • 1
    • 35148880584 scopus 로고    scopus 로고
    • Numeric, verbal, and visual formats of conveying health risks: Suggested best practices and future recommendations
    • Lipkus IM,. Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making. 2007; 27: 696-713.
    • (2007) Med Decis Making. , vol.27 , pp. 696-713
    • Lipkus, I.M.1
  • 2
    • 0023324565 scopus 로고
    • Perception of risk
    • Slovic P,. Perception of risk. Science. 1987; 236: 280-285.
    • (1987) Science. , vol.236 , pp. 280-285
    • Slovic, P.1
  • 3
    • 38849143239 scopus 로고    scopus 로고
    • Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease
    • Siegel CA, Levy LC, Mackenzie TA, et al. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1-6.
    • (2008) Inflamm Bowel Dis. , vol.14 , pp. 1-6
    • Siegel, C.A.1    Levy, L.C.2    MacKenzie, T.A.3
  • 4
    • 0347991877 scopus 로고    scopus 로고
    • The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients
    • Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126: 19-31.
    • (2004) Gastroenterology. , vol.126 , pp. 19-31
    • Colombel, J.F.1    Loftus, Jr.E.V.2    Tremaine, W.J.3
  • 5
    • 34548490280 scopus 로고    scopus 로고
    • Crohn's disease patients' risk-benefit preferences: Serious adverse event risks versus treatment efficacy
    • Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007; 133: 769-779.
    • (2007) Gastroenterology. , vol.133 , pp. 769-779
    • Johnson, F.R.1    Ozdemir, S.2    Mansfield, C.3
  • 6
    • 58149191718 scopus 로고    scopus 로고
    • Are adult patients more tolerant of treatment risks than parents of juvenile patients?
    • Johnson FR, Ozdemir S, Mansfield C, et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal. 2009; 29: 121-136.
    • (2009) Risk Anal. , vol.29 , pp. 121-136
    • Johnson, F.R.1    Ozdemir, S.2    Mansfield, C.3
  • 7
    • 0028908691 scopus 로고
    • Communicating the benefits of chronic preventive therapy: Does the format of efficacy data determine patients' acceptance of treatment?
    • Hux JE, Naylor CD,. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making. 1995; 15: 152-157.
    • (1995) Med Decis Making. , vol.15 , pp. 152-157
    • Hux, J.E.1    Naylor, C.D.2
  • 8
    • 35148872098 scopus 로고    scopus 로고
    • A meta-analysis of the effects of presenting treatment benefits in different formats
    • Covey J,. A meta-analysis of the effects of presenting treatment benefits in different formats. Med Decis Making. 2007; 27: 638-654.
    • (2007) Med Decis Making. , vol.27 , pp. 638-654
    • Covey, J.1
  • 9
    • 67949112671 scopus 로고    scopus 로고
    • Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis
    • Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009; 7: 874-881.
    • (2009) Clin Gastroenterol Hepatol. , vol.7 , pp. 874-881
    • Siegel, C.A.1    Marden, S.M.2    Persing, S.M.3
  • 10
    • 0030666187 scopus 로고    scopus 로고
    • The role of numeracy in understanding the benefit of screening mammography
    • Schwartz LM, Woloshin S, Black WC, et al. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med. 1997; 127: 966-972.
    • (1997) Ann Intern Med. , vol.127 , pp. 966-972
    • Schwartz, L.M.1    Woloshin, S.2    Black, W.C.3
  • 11
    • 0036370180 scopus 로고    scopus 로고
    • Numeracy and the medical student's ability to interpret data
    • Sheridan SL, Pignone M,. Numeracy and the medical student's ability to interpret data. Eff Clin Pract. 2002; 5: 35-40.
    • (2002) Eff Clin Pract. , vol.5 , pp. 35-40
    • Sheridan, S.L.1    Pignone, M.2
  • 12
    • 33847319314 scopus 로고    scopus 로고
    • The effectiveness of a primer to help people understand risk: Two randomized trials in distinct populations
    • Woloshin S, Schwartz LM, Welch HG,. The effectiveness of a primer to help people understand risk: two randomized trials in distinct populations. Ann Intern Med. 2007; 146: 256-265.
    • (2007) Ann Intern Med. , vol.146 , pp. 256-265
    • Woloshin, S.1    Schwartz, L.M.2    Welch, H.G.3
  • 13
    • 12244292659 scopus 로고    scopus 로고
    • Patients' understanding of risk associated with medication use: Impact of European Commission guidelines and other risk scales
    • Berry DC, Raynor DK, Knapp P, et al. Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf. 2003; 26: 1-11.
    • (2003) Drug Saf. , vol.26 , pp. 1-11
    • Berry, D.C.1    Raynor, D.K.2    Knapp, P.3
  • 14
    • 34548572844 scopus 로고    scopus 로고
    • Making numbers matter: Present and future research in risk communication
    • Fagerlin A, Ubel PA, Smith DM, et al. Making numbers matter: present and future research in risk communication. Am J Health Behav. 2007; 31 (Suppl 1): S47-S56.
    • (2007) Am J Health Behav. , vol.31 , Issue.SUPPL. 1
    • Fagerlin, A.1    Ubel, P.A.2    Smith, D.M.3
  • 15
    • 34248549602 scopus 로고    scopus 로고
    • Numeracy skill and the communication, comprehension, and use of risk-benefit information
    • Peters E, Hibbard J, Slovic P, et al. Numeracy skill and the communication, comprehension, and use of risk-benefit information. Health Aff (Millwood). 2007; 26: 741-748.
    • (2007) Health Aff (Millwood). , vol.26 , pp. 741-748
    • Peters, E.1    Hibbard, J.2    Slovic, P.3
  • 16
    • 85047697559 scopus 로고    scopus 로고
    • Frequency or probability? A qualitative study of risk communication formats used in health care
    • Schapira MM, Nattinger AB, McHorney CA,. Frequency or probability? A qualitative study of risk communication formats used in health care. Med Decis Making. 2001; 21: 459-467.
    • (2001) Med Decis Making. , vol.21 , pp. 459-467
    • Schapira, M.M.1    Nattinger, A.B.2    McHorney, C.A.3
  • 17
    • 44949242296 scopus 로고    scopus 로고
    • Immunosuppressant medications and mortality in inflammatory bowel disease
    • Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008; 103: 1428-1435; quiz 1436.
    • (2008) Am J Gastroenterol. , vol.103 , pp. 1428-1435
    • Lewis, J.D.1    Gelfand, J.M.2    Troxel, A.B.3
  • 18
    • 33646147141 scopus 로고    scopus 로고
    • Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
    • Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4: 621-630.
    • (2006) Clin Gastroenterol Hepatol. , vol.4 , pp. 621-630
    • Lichtenstein, G.R.1    Feagan, B.G.2    Cohen, R.D.3
  • 19
    • 48949107161 scopus 로고    scopus 로고
    • National Safety Council. Available at:. Accessed July 22.
    • Odds of Dying, National Safety Council. Available at:. Accessed July 22, 2006.
    • (2006) Odds of Dying
  • 20
    • 0027131566 scopus 로고
    • Intestinal cancer risk and mortality in patients with Crohn's disease
    • Munkholm P, Langholz E, Davidsen M, et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology. 1993; 105: 1716-1723.
    • (1993) Gastroenterology. , vol.105 , pp. 1716-1723
    • Munkholm, P.1    Langholz, E.2    Davidsen, M.3
  • 21
    • 70350684087 scopus 로고    scopus 로고
    • One year data from the SONIC study: A randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy
    • Sandborn W, Rutgeerts P, Reinisch W, et al. One year data from the SONIC study: A randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology. 2009; 136: A-116.
    • (2009) Gastroenterology. , vol.136 , pp. 116
    • Sandborn, W.1    Rutgeerts, P.2    Reinisch, W.3
  • 22
    • 65349165683 scopus 로고    scopus 로고
    • Using a drug facts box to Communicate drug benefits and harms: Two randomized trials
    • Schwartz LM, Woloshin S, Welch HG,. Using a drug facts box to Communicate drug benefits and harms: two randomized trials. Ann Intern Med. 2009; 150: 516-527.
    • (2009) Ann Intern Med. , vol.150 , pp. 516-527
    • Schwartz, L.M.1    Woloshin, S.2    Welch, H.G.3
  • 23
    • 0034132356 scopus 로고    scopus 로고
    • How to do without steroids in inflammatory bowel disease
    • discussion 58.
    • Present DH,. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis. 2000; 6: 48-57; discussion 58.
    • (2000) Inflamm Bowel Dis. , vol.6 , pp. 48-57
    • Present, D.H.1
  • 25
    • 0034798807 scopus 로고    scopus 로고
    • Review article: The limitations of corticosteroid therapy in Crohn's disease
    • Rutgeerts PJ,. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther. 2001; 15: 1515-1525.
    • (2001) Aliment Pharmacol Ther. , vol.15 , pp. 1515-1525
    • Rutgeerts, P.J.1
  • 26
    • 0037018761 scopus 로고    scopus 로고
    • Maintenance infliximab for Crohn's disease: The ACCENT i randomised trial
    • Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
    • (2002) Lancet. , vol.359 , pp. 1541-1549
    • Hanauer, S.B.1    Feagan, B.G.2    Lichtenstein, G.R.3
  • 27
    • 33745923468 scopus 로고    scopus 로고
    • A safety evaluation for progressive multifocal leukoencephalopathy (PML) in greater than 3,500 patients with Crohn's disease, multiple sclerosis (MS), and rheumatoid arhtiritis (RA) previously treated with natalizumab in clinical trials
    • Sandborn WJ, Targan SR,. A safety evaluation for progressive multifocal leukoencephalopathy (PML) in greater than 3,500 patients with Crohn's disease, multiple sclerosis (MS), and rheumatoid arhtiritis (RA) previously treated with natalizumab in clinical trials. Gastroenterology. 2006; 130: A-72.
    • (2006) Gastroenterology. , vol.130 , pp. 72
    • Sandborn, W.J.1    Targan, S.R.2
  • 28
    • 21744455700 scopus 로고    scopus 로고
    • Review article: Practical management of inflammatory bowel disease patients taking immunomodulators
    • Siegel CA, Sands BE,. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005; 22: 1-16.
    • (2005) Aliment Pharmacol Ther. , vol.22 , pp. 1-16
    • Siegel, C.A.1    Sands, B.E.2
  • 29
    • 0024457688 scopus 로고
    • 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity
    • Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989; 111: 641-649.
    • (1989) Ann Intern Med. , vol.111 , pp. 641-649
    • Present, D.H.1    Meltzer, S.J.2    Krumholz, M.P.3
  • 30
  • 31
    • 0038109994 scopus 로고    scopus 로고
    • Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: A prospective cohort study
    • Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003; 125: 32-39.
    • (2003) Gastroenterology. , vol.125 , pp. 32-39
    • Vermeire, S.1    Noman, M.2    Van Assche, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.